Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.

Niu N, Schaid DJ, Abo RP, Kalari K, Fridley BL, Feng Q, Jenkins G, Batzler A, Brisbin AG, Cunningham JM, Li L, Sun Z, Yang P, Wang L.

BMC Cancer. 2012 Sep 24;12:422. doi: 10.1186/1471-2407-12-422.

2.

Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.

Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, Sun Z, Yang P, Wang L.

Clin Cancer Res. 2011 Sep 1;17(17):5801-11. doi: 10.1158/1078-0432.CCR-11-1133. Epub 2011 Jul 20.

3.

Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.

Li D, Wei L, Xu B, Yu D, Chang J, Yuan P, Du Z, Tan W, Shen H, Wu T, Wu C, Lin D.

PLoS One. 2014 Nov 21;9(11):e113574. doi: 10.1371/journal.pone.0113574. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118689.

4.

Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.

Li L, Schaid DJ, Fridley BL, Kalari KR, Jenkins GD, Abo RP, Batzler A, Moon I, Pelleymounter L, Eckloff BW, Wieben ED, Sun Z, Yang P, Wang L.

Pharmacogenet Genomics. 2012 Feb;22(2):105-16. doi: 10.1097/FPC.0b013e32834dd7e2.

5.

Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.

Powrózek T, Mlak R, Krawczyk P, Bartoń S, Biernacka B, Małecka-Massalska T, Milanowski J.

Clin Transl Oncol. 2016 Jan;18(1):33-9. doi: 10.1007/s12094-015-1333-8. Epub 2015 Jul 7.

PMID:
26148901
6.

Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada J, Saijo N, Yoshida T, Tamura T.

J Thorac Oncol. 2011 Jan;6(1):132-8. doi: 10.1097/JTO.0b013e318200f415.

7.

Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.

Vasile E, Tibaldi C, Leon GL, D'Incecco A, Giovannetti E.

J Cancer Res Clin Oncol. 2015 Jul;141(7):1189-94. doi: 10.1007/s00432-014-1880-3. Epub 2014 Dec 14.

PMID:
25504507
8.

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.

Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P.

Pharmacogenomics. 2014;15(12):1565-74. doi: 10.2217/pgs.14.107.

9.

Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA, Johnson C, Wu D, Aakre JA, Molina J, Wang L, Pankratz VS, Yang P.

Clin Cancer Res. 2011 Jun 1;17(11):3830-40. doi: 10.1158/1078-0432.CCR-10-2877.

10.

Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.

Lee Y, Yoon KA, Joo J, Lee D, Bae K, Han JY, Lee JS.

Carcinogenesis. 2013 Feb;34(2):307-13. doi: 10.1093/carcin/bgs356. Epub 2012 Nov 8.

PMID:
23144319
11.

Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.

Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, Kim CS, Kim HJ, Lee JE.

J Thorac Oncol. 2011 Aug;6(8):1320-9. doi: 10.1097/JTO.0b013e3182208e26.

12.

Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.

Lung Cancer. 2012 Sep;77(3):578-84. doi: 10.1016/j.lungcan.2012.04.016. Epub 2012 May 18.

PMID:
22608006
13.

A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.

Han JY, Lee YS, Shin ES, Hwang JA, Nam S, Hong SH, Ghang HY, Kim JY, Yoon SJ, Lee JS.

Pharmacogenomics J. 2014 Feb;14(1):20-7. doi: 10.1038/tpj.2013.7. Epub 2013 Mar 12.

PMID:
23478653
14.

Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.

Lee SY, Kang HG, Yoo SS, Kang YR, Choi YY, Lee WK, Choi JE, Jeon HS, Shin KM, Oh IJ, Kim KS, Lee J, Cha SI, Kim CH, Kim YC, Park JY.

Lung Cancer. 2013 Nov;82(2):330-9. doi: 10.1016/j.lungcan.2013.07.024. Epub 2013 Aug 8.

PMID:
23973201
15.

Genome-wide analysis of survival in early-stage non-small-cell lung cancer.

Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, Haugen A, Wu MC, Wang Z, Su L, Asomaning K, Christiani DC.

J Clin Oncol. 2009 Jun 1;27(16):2660-7. doi: 10.1200/JCO.2008.18.7906. Epub 2009 May 4.

16.

MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.

Xu J, Tian S, Yin Z, Wu S, Liu L, Qian Y, Pei D, Gao W, Xu J, Yin Y, Liu P, Shu Y.

Lung Cancer. 2014 Sep;85(3):442-8. doi: 10.1016/j.lungcan.2014.06.010. Epub 2014 Jun 21.

PMID:
24997136
17.

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P.

J Natl Cancer Inst. 2011 May 18;103(10):817-25. doi: 10.1093/jnci/djr075. Epub 2011 Apr 11.

18.

MicroRNA expression and clinical outcome of small cell lung cancer.

Lee JH, Voortman J, Dingemans AM, Voeller DM, Pham T, Wang Y, Giaccone G.

PLoS One. 2011;6(6):e21300. doi: 10.1371/journal.pone.0021300. Epub 2011 Jun 22.

19.

Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.

Kim SH, Kim MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY, Ling H, Lee GW.

Am J Clin Oncol. 2015 Jun;38(3):294-9. doi: 10.1097/COC.0b013e318297f333.

PMID:
23689644
20.

MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.

Geng JQ, Wang XC, Li LF, Zhao J, Wu S, Yu GP, Zhu KJ.

Tumour Biol. 2016 Feb;37(2):2257-65. doi: 10.1007/s13277-015-3980-3. Epub 2015 Sep 10.

PMID:
26358254

Supplemental Content

Support Center